Advertisement
Document › Details
ADC Therapeutics S.A.. (8/3/21). "Press Release: ADC Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates". Lausanne.
Organisation | ADC Therapeutics S.A. (NYSE: ADCT) | |
Group | ADC Therapeutics (Group) | |
Organisation 2 | FDA (US Food and Drug Administration) | |
Group | United States (govt) | |
Product | loncastuximab tesirine-lpyl (ADCT-402) | |
Product 2 | antibody-drug conjugate (ADC) | |
Person | Martin, Chris (Auven Therapeutics 201506 CEO of ADC Therapeutics before CEO of Spirogen Ltd) | |
Person 2 | Müller, Alexandre (Dynamics Group 202104) | |
Original document
accessed by [iito] on
Record changed: 2023-06-05 |
Advertisement
More documents for ADC Therapeutics (Group)
- [1] ADC Therapeutics S.A.. (7/20/23). "Press Release: ADC Therapeutics Announces Plan to Discontinue the Phase 2 LOTIS-9 Clinical Trial of Zynlonta (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients". Lausanne....
- [2] ADC Therapeutics S.A.. (1/4/23). "Press Release: ADC Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference". Lausanne....
- [3] ADC Therapeutics S.A.. (12/21/22). "Press Release: ADC Therapeutics and Sobi Announce European Commission Approval of Zynlonta (loncastuximab tesirine) for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma". Lausanne....
- [4] ADC Therapeutics S.A.. (12/19/22). "Press Release: ADC Therapeutics Appoints Jose Carmona as Chief Financial Officer". Lausanne....
- [5] ADC Therapeutics S.A.. (11/1/22). "Press Release: ADC Therapeutics Appoints Kristen Harrington-Smith as Chief Commercial Officer and Peter Graham as Chief Legal Officer". Lausanne....
- [6] ADC Therapeutics S.A.. (9/6/22). "Press Release: ADC Therapeutics to Participate in Morgan Stanley’s 20th Annual Global Healthcare Conference". Lausanne....
- [7] ADC Therapeutics S.A.. (8/15/22). "Press Release: ADC Therapeutics Announces $175 Million Senior Secured Term Loan from Owl Rock and Oaktree and Settlement of Existing Senior Secured Convertible Notes". Lausanne....
- [8] ADC Therapeutics S.A.. (7/8/22). "Press Release: ADC Therapeutics Announces Exclusive License Agreement with Sobi to Develop and Commercialize Zynlonta (loncastuximab tesirine-lpyl) in Europe and Select International Territories". Lausanne....
- [9] ADC Therapeutics S.A.. (7/1/22). "Press Release: ADC Therapeutics Appoints Jean-Pierre Bizzari, MD, to Board of Directors". Lausanne....
- [10] ADC Therapeutics S.A.. (6/29/22). "Press Release: ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of Zynlonta (loncastuximab tesirine-lpyl) in Combination with Other Anti-cancer Agents". Lausanne....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top